Cortés J - Search Results

1

Etirinotecan pegol for the treatment of breast cancer.

López-Miranda E, Cortés J. López-Miranda E, et al. Among authors: cortes j. Expert Opin Pharmacother. 2016;17(5):727-34. doi: 10.1517/14656566.2016.1154537. Epub 2016 Mar 10. Expert Opin Pharmacother. 2016. PMID: 26881332 Review.

2

Targeting the microtubules in breast cancer beyond taxanes: the epothilones.

Cortes J, Baselga J. Cortes J, et al. Oncologist. 2007 Mar;12(3):271-80. doi: 10.1634/theoncologist.12-3-271. Oncologist. 2007. PMID: 17405891 Free article. Review.

3

HER2 and hormone receptor-positive breast cancer--blocking the right target.

Cortés J, Saura C, Bellet M, Muñoz-Couselo E, Ramírez-Merino N, Calvo V, Pérez J, Vidal M. Cortés J, et al. Nat Rev Clin Oncol. 2011 May;8(5):307-11. doi: 10.1038/nrclinonc.2010.185. Epub 2010 Dec 14. Nat Rev Clin Oncol. 2011. PMID: 21151204 Review.

4

Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.

Cortes J, Lorca R. Cortes J, et al. Future Oncol. 2011 Mar;7(3):355-64. doi: 10.2217/fon.10.186. Epub 2011 Mar 7. Future Oncol. 2011. PMID: 21375468

5

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Cortes J, et al. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. Lancet. 2011. PMID: 21376385 Clinical Trial.

6

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S. Cortes J, et al. Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Cancer Treat Rev. 2012. PMID: 21550727 Review.

7

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

De Mattos-Arruda L, Cortes J. De Mattos-Arruda L, et al. Among authors: cortes j. Oncologist. 2012;17(5):631-44. doi: 10.1634/theoncologist.2011-0187. Epub 2012 Apr 20. Oncologist. 2012. PMID: 22523199 Free PMC article. Review.

8

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

De Mattos-Arruda L, Cortes J. De Mattos-Arruda L, et al. Among authors: cortes j. Breast. 2012 Aug;21(4):604-7. doi: 10.1016/j.breast.2012.04.002. Epub 2012 May 5. Breast. 2012. PMID: 22560618 Free article.

9

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J. De Mattos-Arruda L, et al. Among authors: cortes j. Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Adv Ther. 2013. PMID: 23881722 Review.

10

Therapeutic antibodies in breast cancer.

Pérez-Garcia J, Muñoz-Couselo E, Cortés J, Scaltriti M. Pérez-Garcia J, et al. Among authors: cortes j. Semin Oncol. 2014 Oct;41(5):576-88. doi: 10.1053/j.seminoncol.2014.07.002. Epub 2014 Jul 21. Semin Oncol. 2014. PMID: 25440604 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,862 results

Search Page

Filters